Monica Capp
Psychiatric/Mental Health · Wake Forest, NCNPI 1366428393
Payments from drug & device makers
Across 223 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$480
- Novo Nordisk$458
- Otsuka America Pharmaceutical, Inc.$358
- Bayer$291
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,177100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $1,225 |
| Neurocrine Biosciences, Inc. | 38 | $1,000 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $480 |
| Novo Nordisk | 22 | $458 |
| Otsuka America Pharmaceutical, Inc. | 21 | $358 |
| Bayer | 3 | $291 |
| E.r. Squibb & Sons, L.L.C. | 6 | $214 |
| Lilly USA, LLC | 6 | $179 |
| Axsome Therapeutics, Inc. | 5 | $164 |
| Lundbeck LLC | 6 | $134 |
| Alkermes, Inc. | 5 | $111 |
| Vanda Pharmaceuticals Inc. | 5 | $96 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Johnson & Johnson | 4 | $77 |
| Pfizer | 4 | $67 |
| Avanir Pharmaceuticals, Inc. | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Amgen | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,177 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $123,674 |
| VraylarCariprazine Hcl | 49 | $70,490 |
| RexultiBrexpiprazole | 18 | $27,230 |
| FarxigaDapagliflozin Propanediol | 16 | $20,756 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $18,151 |
| TrintellixVortioxetine Hydrobromide | 20 | $17,452 |
| XareltoRivaroxaban | 15 | $12,630 |
| Divalproex Sodium ErDivalproex Sodium | 48 | $5,982 |
| Aripiprazole | 79 | $5,655 |
| Lurasidone Hcl | 20 | $5,296 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 46 | $5,103 |
| LivaloPitavastatin Calcium | 13 | $3,617 |
| Vilazodone Hcl | 20 | $2,365 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $1,946 |
| Clonazepam | 100 | $1,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,000 | $123,67415 claims |
| AbbVieVraylar | $1,225 | $70,49049 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $358 | $27,23018 claims |
| Alkermes, Inc.Lybalvi | $111 | $18,15113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $21 | $17,45220 claims |
| Johnson & JohnsonXarelto | $77 | $12,63015 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $29 | $3,61713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Wake Forest
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Hannah NealeyFuquay Varina$75K
- Jessica StoneRocky Mount$63K
- Deborah GranickRaleigh$28K
- Ronald PattersonFayetteville$25K
- Ajay PatelRaleigh$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.